Multiple Myeloma – Landscape & Forecast – Disease Landscape & Forecast

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment durations. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Darzalex-based therapies, is impacting the disease’s treatment algorithm. Although Bristol Myers Squibb’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of treatment, recently approved therapies (GlaxoSmithKline’s Blenrep and Sanofi’s Sarclisa) have expanded the number of options available. CAR T-cell therapies (Bristol Myers Squibb / Bluebird Bio’s Abecma and Janssen’s Carvykti) and the anti-BCMA bispecific agents (Pfizer’s elranatamab and Janssen’s teclistamab) are also expected to compete fiercely, in addition to AbbVie / Roche’s Venclexta / Venclyxto. Nevertheless, immense clinical and commercial potential remains for multiple myeloma therapies with improved efficacy, a novel mechanism of action, and/or the ability to treat underserved patient segments, such as smoldering multiple myeloma.

Questions answered

  • What is the size of the drug-treatable multiple myeloma population, and how do the drug-treatment rates vary by geography, line of therapy, and over time?
  • How will the use of Revlimid and Velcade change over the forecast period, and what impact will generic entry have on the multiple myeloma market?
  • What are thought leaders’ opinions of anti-BCMA agents that are approved or in Phase II / III development, such as the BCMA-targeting antibody-drug conjugate Blenrep, the CAR T-cell therapies Abecma and Carvykti, and the bispecific agents elranatamab and teclistamab?
  • What are the drivers of, and constraints on, the multiple myeloma therapy market?
  • How will the entry of new agents shape this market?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Scope

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with thought-leading hematologist-oncologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Incidence of multiple myeloma by country, segmented by line of therapy and by symptomatic status.

Emerging therapies: Phase III/PR: 3 drugs; coverage of select Phase I and II products.

Table of contents

  • Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast
    • Key updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
      • Q3 2021
        • September 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
    • Key findings
      • Multiple Myeloma - Key findings
        • June 2021
        • May 2021
        • April 2021
    • Market Outlook
      • Key Findings
        • Major-Market Share of Drug Classes for Multiple Myeloma: 2020
        • Major-Market Share of Drug Classes for Multiple Myeloma: 2030
        • Major-Market Sales of Key Drugs in the Multiple Myeloma Market: 2020-2030
        • Major-Market Multiple Myeloma Sales by Line of Therapy: 2020-2030
        • Drug-Treatable Population Share and Major-Market Sales Share in Multiple Myeloma: 2020
        • Drug-Treatable Population Share and Major-Market Sales Share in Multiple Myeloma: 2030
        • Population Positioning of Therapies in Multiple Myeloma
        • Multiple Myeloma SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Multiple Myeloma?
        • What Factors Are Constraining the Market for Multiple Myeloma?
      • Segment-Specific Trends
        • Smoldering Multiple Myeloma
        • First-Line Transplant-Eligible Multiple Myeloma
        • Patient-Share Dynamics of Key Regimens in First-Line Transplant-Eligible Multiple Myeloma in the United States: 2020-2030
        • First-Line Transplant-Ineligible Multiple Myeloma
        • Patient-Share Dynamics of Key Regimens in First-Line Transplant-Ineligible Multiple Myeloma in the United States: 2020-2030
        • Relapsed / Refractory Multiple Myeloma
        • Patient-Share Dynamics of Key Regimens in Second-Line Multiple Myeloma in the United States: 2020-2030
        • Patient-Share Dynamics of Key Regimens in Third-Line Multiple Myeloma in the United States: 2020-2030
        • Patient-Share Dynamics of Key Regimens in Fourth-Line Multiple Myeloma in the United States: 2020-2030
        • Patient-Share Dynamics of Key Regimens in Fifth- to Seventh-Line Multiple Myeloma in the United States: 2020-2030
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Clinical Manifestations of Multiple Myeloma
      • Disease Pathophysiology
        • Overview
        • Plasma Cell and Myeloma Cell Process
      • Risk Factors
        • Select Risk Factors Associated With Multiple Myeloma
      • Staging and Classification
        • Classification of Multiple Myeloma
        • Revised IMWG Classification Criteria of Select Plasma Cell Disorders
        • Staging of Multiple Myeloma
        • Durie-Salmon Staging System for Multiple Myeloma
        • International Staging System for Multiple Myeloma
      • Key Pathways and Drug Targets
        • Drug Targets and Potential Therapies for Multiple Myeloma
        • IMiD-Mediated Disruption of Myeloma Cell-Microenvironment Interactions
        • Potentially Synergistic Antitumor Effects of Proteasome and Aggresome Pathways
        • Biology of Selective Inhibitors of Nuclear Export (SINE)
        • Biology of B-Cell Maturation Antigen (BCMA)
        • Aminopeptidases in Apoptosis of Myeloma Cells
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Disease Definition
        • Methods
        • Sources Used for Diagnosed Incidence of Multiple Myeloma
        • Diagnosed Incident Cases of Multiple Myeloma: 2020-2030
        • Disease Definition
        • Methods
        • Sources Used for Symptomatic Distribution of Multiple Myeloma
        • Diagnosed Incident Cases of Multiple Myeloma by Symptoms: 2020-2030
        • Disease Definition
        • Methods
        • Sources Used for Asymptomaticu00a0Multiple Myelomau00a0Progression to Symptomatic Multiple Myeloma
        • Asymptomatic Cases Progressing to Symptomatic Cases of Multiple Myeloma in the Major Pharmaceutical Markets: 2020-2030
        • Drug-Treatable Cases of Multiple Myeloma: 2020-2030
        • Multiple Myeloma Patient Flow
        • Drug-Treated Cases of Multiple Myeloma: 2020-2030
    • Current treatment
      • Key findings
        • Treatment goals
          • Key endpoints used in clinical trials for multiple myeloma
        • Key current therapies
          • Overview
          • Mechanism of action of key current drug classes used for multiple myeloma
          • Current treatments used for multiple myeloma
          • Market events impacting the use of key current therapies in multiple myeloma
          • Key results from select clinical trials investigating thalomid / thalidomide / thaled for the treatment of multiple myeloma
          • Expert insights: thalomid / thalidomide / thaled
          • Key results from select clinical trials investigating lenalidomide for the treatment of multiple myeloma
          • Ongoing clinical development of lenalidomide
          • Key ongoing clinical trials of lenalidomide in the treatment of multiple myeloma
          • Expert insights: lenalidomide
          • Key results from select clinical trials investigating Pomalyst / Imnovid for the treatment of multiple myeloma
          • Ongoing clinical development of Pomalyst / Imnovid
          • Key ongoing clinical trials investigating Pomalyst / Imnovid in the treatment of multiple myeloma
          • Expert insights: Pomalyst / Imnovid
          • Key results from select clinical trials investigating bortezomib for the treatment of multiple myeloma
          • Ongoing clinical development of bortezomib
          • Key ongoing clinical trials investigating bortezomib in the treatment of multiple myeloma
          • Expert insights: bortezomib
          • Key results from select clinical trials investigating Kyprolis for the treatment of multiple myeloma
          • Ongoing clinical development of Kyprolis
          • Key ongoing clinical trials of Kyprolis in the treatment of multiple myeloma
          • Expert insights: Kyprolis
          • Key results from select clinical trials investigating Ninlaro for the treatment of multiple myeloma
          • Ongoing clinical development of Ninlaro
          • Key ongoing clinical trials of Ninlaro in the treatment of multiple myeloma
          • Expert insights: Ninlaro
          • Key results from select clinical trials investigating Farydak for the treatment of multiple myeloma
          • Ongoing clinical development of Farydak
          • Key ongoing clinical trials investigating Farydak in the treatment of multiple myeloma
          • Expert insights: Farydak
          • Key results from select clinical trials investigating Empliciti for the treatment of multiple myeloma
          • Ongoing clinical development of Empliciti
          • Key ongoing clinical trials investigating Empliciti in the treatment of multiple myeloma
          • Expert insights: Empliciti
          • Key results from select clinical trials investigating Darzalex / Darzalex Faspro for the treatment of multiple myeloma
          • Ongoing clinical development of Darzalex / Darzalex Faspro
          • Key ongoing clinical trials of Darzalex / Darzalex Faspro in the treatment of multiple myeloma
          • Expert insights: Darzalex / Darzalex Faspro
          • Sarclisa
          • Key results from select clinical trials investigating Sarclisa for the treatment of multiple myeloma
          • Ongoing clinical development of Sarclisa
          • Key ongoing clinical trials of Sarclisa in the treatment of multiple myeloma
          • Expert insights: Sarclisa
          • Xpovio / Nexpovio
          • Key results from select clinical trials investigating Xpovio / Nexpovio for the treatment of multiple myeloma
          • Ongoing clinical development of Xpovio / Nexpovio
          • Expert insights: Xpovio / Nexpovio
          • Key results from select clinical trials investigating Blenrep for the treatment of multiple myeloma
          • Ongoing clinical development of Blenrep
          • Key ongoing clinical trials of Blenrep in the treatment of multiple myeloma
          • Expert insights: Blenrep
          • Key results from select clinical trials investigating Pepaxto for the treatment of multiple myeloma
          • Ongoing clinical development of Pepaxto
          • Key ongoing clinical trials of Pepaxto in the treatment of multiple myeloma
          • Expert insights: Pepaxto (melflufen)
          • Key results from select clinical trials investigating Abecma for the treatment of multiple myeloma
          • Ongoing clinical development of Abecma
          • Key ongoing clinical trials of Abecma in the treatment of multiple myeloma
          • Expert insights: Abecma
          • Key results from select clinical trials investigating Carvykti for the treatment of multiple myeloma
          • Analysis of the clinical development program for Carvykti
          • Key ongoing clinical trials investigating Carvykti in the treatment of multiple myeloma
          • Expert insights: Carvykti
        • Medical practice
          • Asymptomatic multiple myeloma
          • First-line transplant-eligible multiple myeloma
          • First-line transplant-ineligible multiple myeloma
          • Relapsed / refractory multiple myeloma
          • Patient characteristics influencing drug selection in multiple myeloma
          • Treatment decision tree for multiple myeloma: United States
          • Treatment decision tree for multiple myeloma: Europe
          • Treatment decision tree for multiple myeloma: Japan
      • Unmet Need Overview
        • Attainment of Unmet Needs
          • Current and Future Attainment of Unmet Needs in Multiple Myeloma
          • Top Unmet Needs in Multiple Myeloma: Current and Future Attainment
      • Emerging Therapies
        • Key Findings
          • Key Emerging Therapies
            • Key Therapies in Development for Multiple Myeloma
            • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Multiple Myeloma
            • Key Results From Select Clinical Trials Investigating Venclexta / Venclyxto for the Treatment of Multiple Myeloma
            • Key Ongoing Clinical Trials of Venclexta / Venclyxto in the Treatment of Multiple Myeloma
            • Analysis of the Clinical Development Program for Venclexta / Venclyxto
            • Expert Insights: Venclexta / Venclyxto
            • Expectations for Market Authorization and Sales Opportunity of Venclexta / Venclyxto in Multiple Myeloma
            • Key Results From Select Clinical Trials Investigating Elranatamab (PF-06863135) for the Treatment of Multiple Myeloma
            • Analysis of the Clinical Development Program for Elranatamab
            • Key Ongoing Clinical Trials Investigating Elranatamab in the Treatment of Multiple Myeloma
            • Expectations for Launch and Sales Opportunity of Elranatamab in Multiple Myeloma
            • Teclistamab
            • Key Results From Select Clinical Trials Investigating Teclistamab for the Treatment of Multiple Myeloma
            • Analysis of the Clinical Development Program for Teclistamab
            • Key Ongoing Clinical Trials Investigating Teclistamab in the Treatment of Multiple Myeloma
            • Expectations for Launch and Sales Opportunity of Teclistamab in Multiple Myeloma
          • Early-Phase Pipeline Analysis
            • Select Compounds in Early-Phase Development for Multiple Myeloma
        • Access and Reimbursement Overview
          • Region-Specific Reimbursement Practices
            • Key Market Access Considerations in Multiple Myeloma: United States
            • General Reimbursement Environment: United States
            • Key Market Access Considerations in Multiple Myeloma: EU5
            • General Reimbursement Environment: EU5
            • Key Market Access Considerations in Multiple Myeloma: Japan
            • General Reimbursement Environment: Japan
        • Appendix
          • Key Abbreviations Related to Multiple Myeloma
          • Multiple Myeloma Bibliography